Inactivation of Chikungunya virus by 1,5 iodonapthyl azide

Virology Journal

Radha K Maheshwari²  Paridhi Gupta¹  Anuj Sharma² 

[1] Department of Biological Sciences, Birla Institute of Technology and Science, Pilani, Rajasthan, India;Department of Pathology, Uniformed Services University of the Health Sciences, 4301 Jones Bridge Road, Bethesda, MD 20814, USA

关键词: Iodonapthyl azide;    Inactivated vaccine;    Chikungunya virus;   

Others  :  1152837
DOI  :  10.1186/1743-422X-9-301

 received in 2012-05-24, accepted in 2012-11-15,  发布年份 2012

【 摘 要 】

Background

Chikungunya virus (CHIKV) is an arthropod borne alphavirus of the family Togaviridae. CHIKV is a reemerging virus for which there is no safe prophylactic vaccine. A live attenuated strain of CHIKV, CHIK181/25,was previously demonstrated to be highly immunogenic in humans, however, it showed residual virulence causing transient arthralgia.

Findings

In this study, we demonstrate the complete inactivation of CHIKV181/25 by 1,5 iodonapthyl azide (INA). No cytopathic effect and virus replication was observed in cells infected with the INA-inactivated CHIKV. However, a reduction in the INA-inactivated CHIK virus-antibody binding capacity was observed by western blot analysis.

Conclusion

INA completely inactivated CHIKV and can further be explored for developing an inactivated-CHIKV vaccine.

【 授权许可】

   
2012 Sharma et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

【 参考文献 】

• [1]Sharma A, Raviv Y, Puri A, Viard M, Blumenthal R, Maheshwari RK: Complete inactivation of Venezuelan equine encephalitis virus by 1,5-iodonaphthylazide. Biochem Biophys Res Commun 2007, 358:392-398.
• [2]Sharma A, Gupta P, Glass PJ, Parker MD, Maheshwari RK: Safety and protective efficacy of INA-inactivated Venezuelan equine encephalitis virus: implication in vaccine development. Vaccine 2011, 29:953-959.
• [3]Das T, Jaffar-Bandjee MC, Hoarau JJ, Krejbich Trotot P, Denizot M, Lee-Pat-Yuen G, Sahoo R, Guiraud P, Ramful D, Robin S, Alessandri JL, Gauzere BA, Gasque P: Chikungunya fever: CNS infection and pathologies of a re-emerging arbovirus. Prog Neurobiol 2010, 91:121-129.
• [4]Chen LH, Wilson ME: Dengue and chikungunya infections in travelers. Curr Opin Infect Dis 2010, 23:438-444.
• [5]Tsetsarkin KA, Vanlandingham DL, McGee CE, Higgs S: A single mutation in chikungunya virus affects vector specificity and epidemic potential. PLoS Pathog 2007, 3:e201.
• [6]Martin E, Moutailler S, Madec Y, Failloux AB: Differential responses of the mosquito Aedes albopictus from the Indian Ocean region to two chikungunya isolates. BMC Ecol 2010., 10(8) BioMed Central Full Text
• [7]Chhabra M, Mittal V, Bhattacharya D, Rana U, Lal S: Chikungunya fever: a re-emerging viral infection. Indian J Med Microbiol 2008, 26:5-12.
• [8]Edelman R, Tacket CO, Wasserman SS, Bodison SA, Perry JG, Mangiafico JA: Phase II safety and immunogenicity study of live chikungunya virus vaccine TSI-GSD-218. AmJTrop Med Hyg 2000, 62:681-685.
• [9]Wang E, Volkova E, Adams AP, Forrester N, Xiao SY, Frolov I, Weaver SC: Chimeric alphavirus vaccine candidates for chikungunya. Vaccine 2008, 26:5030-5039.
• [10]Akahata W, Yang ZY, Andersen H, Sun S, Holdaway HA, Kong WP, Lewis MG, Higgs S, Rossmann MG, Rao S, Nabel GJ: A virus-like particle vaccine for epidemic Chikungunya virus protects nonhuman primates against infection. Nat Med 2010, 16:334-338.
• [11]Tiwari M, Parida M, Santhosh SR, Khan M, Dash PK, Rao PV: Assessment of immunogenic potential of Vero adapted formalin inactivated vaccine derived from novel ECSA genotype of Chikungunya virus. Vaccine 2009, 27:2513-2522.
• [12]Muthumani K, Lankaraman KM, Laddy DJ, Sundaram SG, Chung CW, Sako E, Wu L, Khan A, Sardesai N, Kim JJ, Vijayachari P, Weiner DB: Immunogenicity of novel consensus-based DNA vaccines against Chikungunya virus. Vaccine 2008, 26:5128-5134.
• [13]Couderc T, Khandoudi N, Grandadam M, Visse C, Gangneux N, Bagot S, Prost JF, Lecuit M: Prophylaxis and therapy for Chikungunya virus infection. J Infect Dis 2009, 200:516-523.
• [14]Bercovici T, Gitler C: 5-[125I]Iodonaphthyl azide, a reagent to determine the penetration of proteins into the lipid bilayer of biological membranes. Biochemistry 1978, 17:1484-1489.
• [15]Raviv Y, Viard M, Bess JW Jr, Chertova E, Blumenthal R: Inactivation of retroviruses with preservation of structural integrity by targeting the hydrophobic domain of the viral envelope. J Virol 2005, 79:12394-12400.
• [16]Warfield KL, Swenson DL, Olinger GG, Kalina WV, Viard M, Aitichou M, Chi X, Ibrahim S, Blumenthal R, Raviv Y, Bavari S, Aman MJ: Ebola virus inactivation with preservation of antigenic and structural integrity by a photoinducible alkylating agent. J Infect Dis 2007, 196(Suppl 2):S276-S283.
• [17]Raviv Y, Blumenthal R, Tompkins SM, Humberd J, Hogan RJ, Viard M: Hydrophobic inactivation of influenza viruses confers preservation of viral structure with enhanced immunogenicity. J Virol 2008, 82:4612-4619.
• [18]Sagripanti J, Marschall H, Voss L, Hülseweh B: Photochemical Inactivation of Alpha- and Poxviruses. Photochem Photobiol 2003, 87(6):1369-1378.
• [19]Kumar M, Arankalle VA: Evaluation of recombinant E2 protein-based and whole-virus inactivated candidate vaccines against chikungunya virus. Vaccine 2012, 30:6142-6149.